Novartis discloses PML case in Gilenya patient, but blames Tysabri
This article was originally published in Scrip
Executive Summary
Swiss drug and vaccine maker Novartis disclosed a patient with JCV antibody positive multiple sclerosis taking the firm's medicine Gilenya (fingolimod) was diagnosed with progressive multifocal leukoencephalopathy (PML), a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system.